Solar Ultraviolet Radiation

Global burden of disease from solar ultraviolet radiation

Robyn Lucas Tony McMichael Wayne Smith Bruce Armstrong

Editors Annette Prüss-Üstün, Hajo Zeeb, Colin Mathers, Michael Repacholi



WHO Library Cataloguing-in-Publication Data

Solar ultraviolet radiation : global burden of disease from solar ultraviolet radiation / Robyn Lucas ... [et al.] ; editors, Annette Prüss-Üstün ... [et al.].

(Environmental burden of disease series; no. 13.)

1.Sunlight - adverse effects. 2.Ultraviolet rays - adverse effects. 3.Risk assessment. 4.Cost of illness. 5.Skin - radiation effects. 6.Eye - radiation effects. I.Lucas, Robyn. II.Prüss-Üstün, Annette. III.World Health Organization. IV.Series: Environmental burden of disease series; no. 13.

ISBN 92 4 159440 3 ISBN 978 92 4 159440 0 ISSN 1728-1652 (NLM classification: WD 605)

© World Health Organization 2006

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: bookorders@who.int). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to Marketing and Dissemination, at the above address (fax: +41 22 791 4806; email: permissions@who.int).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either express or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

The named authors alone are responsible for the views expressed in this publication.

Printed by the WHO Document Production Services, Geneva, Switzerland.

Table of Contents

| Preface | | Vi | |
|----------------|---|------|--|
| Affiliation | ns and acknowledgements | vii | |
| Abbrev | ations | viii | |
| Summa | ry | 1 | |
| 1. | Background | 2 | |
| | 1.1 Introduction | 2 | |
| | 1.2 Comparative risk assessment | | |
| | 1.3 Definition of the risk factor | | |
| | 1.4 Measurement of the risk factor | | |
| | 1.5 Defining the counterfactual exposure | | |
| 2. | Methods | | |
| | 2.1 Outcomes to be assessed | | |
| | 2.2 Estimation of risk factor-disease relationships | | |
| | 2.3 Evaluation of population attributable fraction | | |
| | · | | |
| 3. | Burden of Disease Assessment | 18 | |
| | 3.1 Diseases with pre-existing BOD analyses completed | | |
| | 3.2 Diseases where adequate epidemiological data are available | | |
| | 3.3 Diseases with scanty global data | | |
| 4. | Outcome assessment for diseases caused by excessive UVR exposure | | |
| | 4.1 Cutaneous malignant melanoma | | |
| | 4.2 Squamous cell carcinoma | | |
| | 4.3 Basal cell carcinoma | | |
| | 4.5 Sunburn | | |
| | 4.6 Cortical cataract | | |
| | 4.7 Pterygium | | |
| | 4.8 Carcinoma of the cornea and conjunctiva | | |
| | 4.9 Reactivation of herpes labialis | | |
| 5. | Potential disease burden caused by complete removal of UVR exposure | 72 | |
| 6. | Sources of error or uncertainty | 77 | |
| 7. | Conclusion | 78 | |
| 8. | Future directions | 80 | |
| Refere | ces | 83 | |
| Annexe | 5 | 88 | |
| Annex | Literature Review | 88 | |
| Annex | production of the contract of | | |
| Δ. | studies of disease distribution | | |
| Annex Annex | | | |
| Annex | | | |
| Annex | · | | |
| Annex | · · · · · · · · · · · · · · · · · · · | 206 | |

List of tables

| Table 2.1 | Candidate, and selected, health outcomes to be assessed for the burden of disease related to ultraviolet radiation. | 11 |
|------------|---|----|
| Table 4.1 | Incident cases of Malignant Melanoma 2000 | 22 |
| Table 4.2 | Mortality from Malignant Melanoma 2000 (0.1% of total global mortality) | 23 |
| Table 4.3 | Disease burden due to malignant melanoma in DALYs (000) | 24 |
| Table 4.4 | Disease burden from malignant melanoma attributable to ultraviolet radiation DALYs (000) – upper estimates | 25 |
| Table 4.5 | Disease burden from malignant melanoma attributable to ultraviolet radiation DALYs (000) – lower estimates | 26 |
| Table 4.6 | Incident cases of SCC | 30 |
| Table 4.7 | Deaths from SCC | 31 |
| Table 4.8 | Disease burden due to SCC in DALYs (000) | 32 |
| Table 4.9 | Disease burden from SCC attributable to ultraviolet radiation DALYs (000) – upper estimates | 33 |
| Table 4.10 | Disease burden from SCC attributable to ultraviolet radiation DALYs (000) – lower estimates | 34 |
| Table 4.11 | Incident cases of BCC | 37 |
| Table 4.12 | Deaths from BCC in 2000 | 38 |
| Table 4.13 | Disease burden due to BCC in DALYs (000) | 39 |
| Table 4.14 | Disease burden from BCC attributable to ultraviolet radiation DALYs (000) – upper estimates | 40 |
| Table 4.15 | Disease burden from BCC attributable to ultraviolet radiation DALYs (000) – lower estimates | 41 |
| Table 4.16 | Prevalent persons with solar keratoses | 44 |
| Table 4.17 | Burden of disease due to solar keratoses (=attributable BOD) DALYs (000) | 45 |
| Table 4.18 | Incident cases of sunburn 2000 | 48 |
| Table 4.19 | Burden of disease due to sunburn (attributable BOD) DALYs (000) | 49 |
| Table 4.20 | Incident cataracts 2000 (from GBD 2000, (99)) | 51 |
| Table 4.21 | Burden of disease from cataract DALYs (000) (from GBD 2000, (99)) | 52 |
| Table 4.22 | Burden of disease due to cortical cataract DALYs (000) | 53 |
| Table 4.23 | Disease burden from cataract attributable to UVR DALYs (000) | 54 |
| Table 4.24 | Prevalence (persons) of pterygium 2000 | 57 |
| Table 4.25 | Burden of disease from pterygium DALYs (000) | 58 |
| Table 4.26 | Disease burden from pterygium attributable to UVR DALYs (000) – upper estimates | 59 |
| Table 4.27 | Disease burden from pterygium attributable to UVR DALYs (000) – lower estimates | 60 |
| Table 4.28 | Incident cases of SCCC (2000) | 63 |
| Table 4.29 | Burden of disease from SCCC DALYs (000) | 64 |
| Table 4.30 | Disease burden from SCCC attributable to UVR DALYs (000) – upper estimates | 65 |
| Table 4.31 | Disease burden from SCCC attributable to UVR DALYs (000) – lower estimates | 66 |
| Table 4.32 | Incident herpes labialis 2000 | 68 |
| Table 4.33 | Burden of disease from RHL DALYs (000) | 69 |
| Table 4.34 | Disease burden from RHL attributable to UVR DALYs (000) – upper estimates | 70 |
| Table 4.35 | Disease burden from RHL attributable to UVR DALYs (000) – lower estimates | 71 |

| Table 5.1 | Proposal for staging of vitamin D deficiency ¹ | 73 |
|------------|--|------|
| Table 5.2 | Incident cases of vitamin D deficiency 2000 under a scenario of zero UVR exposure | .75 |
| Table 5.3 | Potential disease burden due to complete removal of UVR exposure, DALYs (000) | .76 |
| Table 7.1 | Burden of disease due to excessive UVR exposure, DALYs (000) and deaths | .78 |
| | | |
| List of | f figures | |
| Figure 1.1 | Causal Web for Health Impacts due to Ultraviolet Radiation | 3 |
| Figure 1.2 | Monthly averaged annual ambient erythemally weighted UVR, 1997-2003 | 6 |
| Figure 2.1 | Schematic diagram of the relation between ultraviolet radiation (UVR) exposure and the burden of disease | 6 |
| Figure 2.2 | Distribution of UVR exposure in a theoretical population | .16 |
| Figure 2.3 | Distribution of UVR exposure in two different (theoretical) populations | . 16 |
| Figure 3.1 | Methods of calculating attributable burden | . 18 |
| Figure 4.1 | Disease model for SCC | . 29 |
| Figure 4.2 | Disease model for BCC – all regions | . 36 |
| Figure 4.3 | Disease model for solar keratoses | .43 |
| Figure 4.4 | Disease model for sunburn | .47 |
| Figure 4.5 | Disease model for pterygium | . 56 |
| Figure 4.6 | Disease model for SCCC - ABC regions | 62 |

Preface

Human exposure to solar ultraviolet radiation has important public health implications. Evidence of harm associated with overexposure to UV has been demonstrated in many studies. Skin cancer and malignant melanoma are among the most severe health effects, but a series of other health effects have been identified. The current report provides a quantification of the global disease burden associated with UV. The information presented forms a knowledge base for the prevention of adverse effects of UV exposure that is achievable with known and accessible interventions. UV prevention focuses on protecting the skin and other organs from UV radiation. On the other hand, a moderate degree of UV exposure is necessary for the production of Vitamin D which is essential for bone health. Additionally, evidence emerges that low Vitamin D levels are likely to be associated with other chronic diseases. Thus, public health policy on ultraviolet radiation needs to aim at preventing the disease burden associated both with excessive and with insufficient UV exposure.

This volume is part of a series on global estimates of disease burden caused by environmental risks, and guides for estimating the disease burden from specific risks at country or local level. This Environmental Burden of Disease (EBD) series responds to the need to quantify environmental health risks as input to rational policy making. Quantification of disease will provide information on the health gains that could be achieved by targeted action on protecting against specific environmental risks to health. An introductory volume (No. 1 of the series) provides further details on methods used for such quantification.

The methods for environmental burden of disease are part of a larger initiative - WHO has recently analysed 26 risk factors worldwide in the World Health Report (WHO, 2002). In 2006, a global estimate of the health impacts from environmental risks has shown that the 24% of global disease is due to the "modifiable" part of the environment¹.

A separate guide is being prepared to assist in the estimation of health impacts from UV radiation at country level.

_

¹ Preventing disease through healthy environments - towards an estimate of the global burden of disease. WHO, Geneva, 2006.

Affiliations and acknowledgements

The World Health Organization, through its INTERSUN programme, is actively engaged in protecting the public from health hazards of ultraviolet radiation. In the framework of this programme, an assessment of the global disease burden associated with solar ultraviolet radiation was performed by the National Centre for Epidemiology and Population Health (NCEPH) in Australia, implementing a contract between WHO and the New South Wales Cancer Council.

The principal authors of this report are:

- Dr. Robyn Lucas, National Centre for Epidemiology and Population Health, Canberra, Australia
- Prof. Tony McMichael, National Centre for Epidemiology and Population Health, Canberra, Australia
- Prof. Wayne Smith, Centre for Clinical Epidemiology and Biostatistics, Newcastle University, Australia.
- Prof. Bruce Armstrong, School of Public Health, The University of Sydney, Australia

The WHO and the authors wish to acknowledge the assistance of Ivan Hanigan (NCEPH) with reference retrieval and GIS mapping of population and UVR; Dr Diarmid Campbell-Lendrum (WHO) for his discussion of comparative risk assessment methodology; Dr Jenny Lucas (Bone Fellow, Auckland Hospital, New Zealand) for her help in the understanding of influences of vitamin D on the skeletal system; Dr Robin Marks for his helpful comments on disease models for skin cancers; and Dr Simon Hales for GIS expertise. Dr William B. Grant (Sunarc, USA), Reviewers at the German Bundesamt für Strahlenschutz, the US Environmental Protection Agency, the WHO (Drs Kate Strong and Andreas Ullrich) as well as Professor Rona M MacKie (University of Glasgow, UK) reviewed earlier drafts of the document.

Editorial and scientific support at WHO was provided by Drs. Annette Prüss-Üstün, Hajo Zeeb, Colin Mathers and Michael Repacholi.

Abbreviations

BCC Basal cell carcinoma

CMM Cutaneous malignant melanoma

DALY Disability-adjusted life year

GBD Global burden of disease

NMSC Non-melanoma skin cancer

PAF Population attributable fraction

RHL Reactivation of herpes labialis

SCC Squamous cell carcinoma

SCCC Squamous cell carcinomas of the cornea and the conjunctiva

UVR Ultraviolet radiation

预览已结束, 完整报告链接和二维码如下:

https://www.yunbaogao.cn/report/index/report?reportId=5_29759

